October 24, 2007
Phase Bioscience Announces Series B Investment from Johnson & Johnson Development Corporation, Fletcher Spaght Ventures and Hatteras Venture Partners
Durham, NC – Phase Bioscience, Inc., a development stage biotechnology company, announced today that it has successfully raised an additional $5.4 million in Series B financing, bringing the total Series B round to $6.6 million.
June 7, 2007
Viamet Pharmaceuticals Raises $4 Million Round of Financing
Drug Discovery and Development Company Focused on Metalloenzymes Closes Series A Round Research Triangle Park , NC – Viamet Pharmaceuticals Inc., a biotechnology company targeting metalloenzymes in the fields of infectious disease, inflammation and oncology, announced today that it has closed a $4 million Series A financing round.
February 9, 2007
Hatteras Announces Initial Closing of Fund Focused on Early-Stage Companies in the Southeast
DURHAM , NC – Hatteras Venture Partners announced today the first closing of its third venture capital fund, Hatteras Venture Partners III, LP (HVP III). The Fund has secured commitments for $60 million to invest in seed and early-stage companies in biopharmaceuticals, medical devices, diagnostics and related opportunities in human medicine. The ultimate fund size is expected to be $100 million. HVP III may invest in opportunities throughout the country but will focus on forming and leading companies in the southeastern United States, where the level of National Institutes of Health-funded research is high but the availability of early-stage venture capital is limited.